ReviewVaccines2018
Challenges and Achievements in Prevention and Treatment of Smallpox.
Review in Vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Evidence of Long-Distance Aerial Convection of Variola Virus and Implications for Disease Control.Viruses · 2019Pooled it
- Monkey pox (Mpox): pathogenesis, genetic shifts, vaccination strategies and clinical insights.Archives of microbiology · 2026Review
- Vaccinia virus mRNAs containing long 5'-poly(A)-leaders lack a canonical 5'-methylguanosine cap.Nature communications · 2025Article
- An mRNA vaccine against monkeypox virus inhibits infection by co-activation of humoral and cellular immune responses.Nature communications · 2025Article
- Review
- Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection.Nature communications · 2024Article
- From Outbreaks to Artificial Intelligence: A Comprehensive Review of Monkeypox Virus Epidemiology, Diagnosis, Treatment, Vaccination, and Deep Learning Applications.Journal of tropical medicine · 2024Review
- [Adverse Reactions after Smallpox Vaccination and Adverse Reaction Treatment by Vaccinia Immune Globulin].Jugan geon-gang gwa jilbyeong · 2023Review
- Monkeypox: a review of epidemiological modelling studies and how modelling has led to mechanistic insight.Epidemiology and infection · 2023Review
- Overview of Diagnostic Methods, Disease Prevalence and Transmission of Mpox (Formerly Monkeypox) in Humans and Animal Reservoirs.Microorganisms · 2023Review
- Vaccines against monkeypox.Medicina clinica (English ed.) · 2023Review
- Chain-Engineering-Based De Novo Drug Design against MPXVgp169 Virulent Protein of Monkeypox Virus: A Molecular Modification Approach.Bioengineering (Basel, Switzerland) · 2022Article
- Therapeutic strategies to address monkeypox.Expert review of anti-infective therapy · 2022Article
- Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine.Scientific reports · 2022Article
- Poxviruses Bearing DNA Polymerase Mutations Show Complex Patterns of Cross-Resistance.Biomedicines · 2022Article
- Emerging and Re-Emerging Diseases.Pathogens (Basel, Switzerland) · 2021Article
- An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.Expert review of anti-infective therapy · 2021Review
- IMVAMUNEVaccines · 2020Article
- Article
- Diagnosis of Imported Monkeypox, Israel, 2018.Emerging infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Declaration of smallpox eradication by the WHO in 1980 led to discontinuation of the worldwide vaccination campaign. The increasing percentage of unvaccinated individuals, the existence of its causative infectious agent variola virus (VARV), and the recent synthetic achievements increase the threat of intentional or accidental release and reemergence of smallpox. Control of smallpox would require an emergency vaccination campaign, as no other protective measure has been approved to achieve eradication and ensure worldwide protection. Experimental data in surrogate animal models support the assumption, based on anecdotal, uncontrolled historical data, that vaccination up to 4 days postexposure confers effective protection. The long incubation period, and the uncertainty of the exposure status in the surrounding population, call for the development and evaluation of safe and effective methods enabling extension of the therapeutic window, and to reduce the disease manifestations and vaccine adverse reactions. To achieve these goals, we need to evaluate the efficacy of novel and already licensed vaccines as a sole treatment, or in conjunction with immune modulators and antiviral drugs. In this review, we address the available data, recent achievements, and open questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.